Composition with double effects of resisting motion sickness and fatigue as well as preparation method and application of composition

Abstract

According to the composition with the double effects of resisting motion sickness and fatigue and the preparation method and application of the composition, 10-20 parts of the gastrodia elata serving as a main raw material and 2-8 parts of the fresh ginger, 5-10 parts of the tamarind fruits, 0.5-2 parts of the pericarpium citri reticulatae, 3-6 parts of the ginseng, 1-5 parts of the spina date seeds, 2-5 parts of the rosemary and 1-5 parts of the poria cocos are compounded to obtain the composition with the double effects of resisting motion sickness and fatigue, and the composition is high in safety and free of toxic and side effects. The defects of low bioavailability, poor dispersity, low compliance, slow dissolution of active ingredients and slow effect of traditional gastrodia elata slicing or powdering are overcome, the superfine powder is prepared through a superfine grinding technology, the superfine powder is convenient to absorb by a human body, the utilization rate is increased, and the functional active ingredients are more beneficial. By optimizing the components, the food functional glue which is reddish brown, rich in luster, good in transparency and chewiness, fine and smooth in mouth, moderate in sour and sweet taste, special in fresh scent and soft in pungency degree is obtained, can effectively relieve the motion sickness symptom, and is high in safety and free of toxic and side effects.

Description

Technical Field

[0001] The present invention relates to a composition with dual functions of anti-motion sickness and anti-fatigue, and in particular to a composition with dual functions of anti-motion sickness and anti-fatigue, and a preparation method and application thereof, belonging to the technical field of functional foods. Background Art

[0002] Motion sickness (MS) refers to a disease caused by the dysfunction of the body's central and autonomic nervous systems due to the accelerated movements of swinging, rotating, bumping, etc. produced by vehicles, ships, airplanes, etc., which stimulates the vestibular nerves in the human inner ear to produce excessive bioelectricity. It is commonly known as seasickness, carsickness, or airsickness. Its clinical manifestations include nausea, pale complexion, cold sweats, dizziness, salivation, vomiting, and even serious symptoms such as arrhythmia, collapse, and shock.

[0003] At present, one of the main means of preventing and treating motion sickness is to take anti-motion sickness drugs such as anticholinergics, antihistamines, sympathomimetics, etc. Although these drugs can prevent and treat or alleviate the symptoms of motion sickness to a certain extent, they bring side effects such as drowsiness, lack of concentration, decreased physical fitness or addiction.

[0004] There are relatively few patents related to the dual effects of anti-motion sickness and anti-fatigue, among which:

[0005] CN115777749A specifically relates to a gastrodia elata biscuit and a preparation method thereof. The composition comprises 3-5 parts of gastrodia elata, 10-20 parts of tuckahoe, 10-20 parts of coix seeds, 10-20 parts of black sesame, 10-20 parts of walnuts and 10-20 parts of jujube. The prepared gastrodia elata biscuit has a complete appearance, uniform color, crisp taste, moderate sweetness, and a black sesame aroma, which covers up the bad smell of gastrodia elata. The tissue structure is layered, the pores are fine, and it is rich in nutrition, which provides a new idea for the research and development of gastrodia elata in health food.

[0006] CN115956676A discloses a plant-derived compound combination for preventing and treating motion sickness. The plant-derived compound combination is made of pimaric acid, isorhamnetin, imperatorin, erucic acid, kaurenoic acid, hyperoside and scopoletin. The results of animal behavior experiments show that the combination can effectively improve the symptoms of motion sickness, regulate the anxiety behavior and stress state of mice after motion sickness occurs, improve the coordination ability of mice, and prevent the occurrence of physical fatigue in mice. It is a healthy plant-derived medicine for preventing and treating motion sickness.

[0007] Therefore, there is an urgent need to find functional foods that are effective, have few side effects, and have both anti-motion sickness and anti-fatigue effects. Summary of the invention

[0008] In order to solve the deficiencies of the prior art, the purpose of the present invention is to provide a composition having both anti-motion sickness and anti-fatigue effects and a preparation method and application thereof.

[0009] In order to achieve the above object, the present invention adopts the following technical solution:

[0010] The composition has the dual effects of anti-motion sickness and anti-fatigue, comprising, by weight: 10-20 parts of gastrodia elata, 2-8 parts of ginger, and 3-6 parts of ginseng.

[0011] In parts by mass, the composition further comprises 5-10 parts of tamarind, 0.5-2 parts of dried tangerine peel, 1-5 parts of spiny jujube seeds, 2-5 parts of rosemary, and 1-5 parts of poria.

[0012] The preparation method of the composition with dual effects of anti-motion sickness and anti-fatigue is as follows: each component in claim 1 or 2 is added into a grinder and crushed to obtain coarse powder; the coarse powder of each component is then crushed into ultrafine powder with a particle size of 1-10um by a low-temperature cell-grade grinder, and mixed.

[0013] Furthermore, the above composition is used in the preparation of functional food.

[0014] Furthermore, the above composition is used in the preparation of medicines.

[0015] Furthermore, the above composition is used in the preparation of functional drinks.

[0016] Application of the above composition in food preparation.

[0017] The present invention is beneficial in that:

[0018] The present invention discloses a composition having dual effects of anti-motion sickness and anti-fatigue, and its preparation method and application. The composition is prepared by using raw materials of medicine and food, such as Gastrodia elata, ginger and ginseng, as main ingredients, and compounded with various plant-based raw materials of medicine and food, such as tamarind, tangerine peel, jujube seed, rosemary, and Poria cocos, with high safety and no toxic side effects. The composition solves the problems of low bioavailability, poor dispersibility, and low compliance of traditional Gastrodia elata tubers after drying and slicing or powdering, and more importantly, improves the shortcomings of slow dissolution and slow onset of active ingredients; ultrafine powder of 1-10um is obtained by adopting ultrafine powdering of cell-level crushing, which helps to retain the nutrients in the raw materials, improve the taste of food, enhance the flexibility of food processing, extend the shelf life, improve the solubility of the product, facilitate human absorption, make the utilization rate higher, and be more beneficial to the functional active ingredients. Through multiple groups of animal experiments, MSI, balance beam, spontaneous activity distance, number of activities, and weighted swimming time are used as indicators to verify that the efficacy composition of the present invention has significant anti-motion sickness and anti-fatigue effects.

[0019] By further proportioning the raw material components and optimizing the process, it can be applied to functional foods, functional beverages and medicines. Compared with traditional Chinese medicine with heavy taste, low acceptance and complicated eating method, it has the advantages of being ready to eat right after opening the bag, good taste, rapid energy supply, prevention and relief of motion sickness symptoms, improved body endurance, high safety and no toxic side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is the particle size distribution diagram of Gastrodia elata coarse powder.

[0021] Figure 2 This is a picture of the ultrafine powder of Gastrodia elata.

[0022] Figure 3 It is a bar graph of serum index levels (A: histamine, B: acetylcholine, C: adrenocortical hormone). DETAILED DESCRIPTION

[0023] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0024] 1Raw materials

[0025] The raw materials and reagents of the present invention are all commercially available, among which:

[0026] Gastrodia elata was fresh winter gastrodia (Gastrodia elata Bl.), collected from the Gastrodia elata plantation in Xiaocaoba Town, Yiliang County, Zhaotong City, Yunnan Province.

[0027] Tangerine peel, ginger, ginseng, rosemary, poria, spinach seed, and tamarind were purchased from Beijing Tong Ren Tang Pharmacy.

[0028] Gelatin, agar, and modified starch were purchased from Henan Wanbang Chemical Technology Co., Ltd.

[0029] Korean white sugar, TS Corporation.

[0030] Fructose corn syrup, type 55, was purchased from Hubei Qianfengxiang Food Co., Ltd.

[0031] Dimenhydrinate lozenges (Yihanning), manufactured by Beijing Yimin Pharmaceutical Co., Ltd., were purchased from Baixing Sunshine Pharmacy.

[0032] 2. Instruments and Equipment

[0033] Chinese herbal medicine grinder (DFY-200C), XDW-6B vibration type low temperature ultrafine grinder, Nanda Micro Machinery Co., Ltd.

[0034] Inverted microscope, laser particle size detector, Mastersizer 2000 (Malvern, UK).

[0035] Field emission scanning electron microscope, USA-FEI-Quanta 250FEG.

[0036] Ultraviolet spectrophotometer, Shanghai Yuanxi Instrument Co., Ltd.-UV-5100.

[0037] BSA-423S precision electronic balance, Shanghai Precision Instruments Co., Ltd.

[0038] PRACTUM313-1CN analytical balance, Practum (Sartorius).

[0039] Handheld refractometer, Chizhou Schneider Intelligent Technology Co., Ltd.

[0040] JD-XZY type balance rotator, Shanghai Jide Teaching Experimental Equipment Factory.

[0041] SA214 open field test system, Anhui Saiangsi Medical Technology Co., Ltd.

[0042] LDZM-40AL vertical pressure steam sterilizer, Shanghai Shen'an Medical Equipment Factory.

[0043] 3. Mice for animal experiments

[0044] 3.1 120 healthy male mice of BALB / c strain, weighing 20-25 g, SPF grade. Purchased by Nanjing Agricultural University Animal Ethics Committee, the experimental license number is NJAU.No.20240606116.

[0045] 3.2 Mouse serum kit

[0046] Mouse adrenocorticotropic hormone (ACTH) ELISA detection kit, mouse acetylcholine (ACH) ELISA detection kit, mouse histamine (HIS) ELISA detection kit were purchased from Shanghai Youxuan Biotechnology Co., Ltd.

[0047] 4 Experimental process

[0048] 4.1 Raw material preparation

[0049] The coarse powders of Gastrodia elata, ginger, ginseng, rosemary, Poria cocos, Ziziphus jujuba seeds, Tamarindus indica and dried orange peel were pulverized by XDW-6B vibration low-temperature cell-grade pulverizer to prepare ultrafine powder.

[0050] 4.2 Particle size detection

[0051] like Figure 1 As shown, the particle size distribution diagram of the coarse powder of Gastrodia elata detected by laser particle size analyzer, the powder particle size is about 34.8um.

[0052] Figure 2This is a picture of the ultrafine powder of Gastrodia elata, the particle size of the powder is about 8um.

[0053] 4.3 Compositions with dual effects of anti-motion sickness and anti-fatigue

[0054] The formula comprises, by weight, main components: 10-20 parts of gastrodia elata, 2-8 parts of ginger, 3-6 parts of ginseng, and secondary components: 5-10 parts of tamarind, 0.5-2 parts of tangerine peel, 1-5 parts of spiny jujube kernel, 2-5 parts of rosemary, and 1-5 parts of poria.

[0055] The preparation method comprises the following steps: adding each component into a pulverizer and pulverizing the components to obtain coarse powders respectively; and then using a low-temperature cell-grade pulverizer to pulverize the coarse powders of each component into ultrafine powders with a particle size of 1-10 μm for standby use.

[0056] The formulations of Examples 1-4 are shown in Table 1 below:

[0057] Table 1 Formula table of Examples 1-4

[0058]

[0059]

[0060] 4.3.1 Preparation of composition

[0061] According to the weight percentages in Table 1 above, the ultrafine powders of Gastrodia elata, ginger, ginseng, rosemary, Poria cocos, spiny jujube seeds, tamarind and tangerine peel were weighed respectively and mixed to prepare a composition.

[0062] 5 Animal experiments based on Examples 1-4

[0063] 5.1 Animal grouping and drug administration (composition)

[0064] The mice were randomly divided into 6 groups, 8 in each group, and each mouse was numbered and provided with food and water. The ambient temperature was (25±1)℃ and the relative humidity was (70±2)%, and the mice were adapted to feeding for 7 days.

[0065] The product dosage is determined according to the "Announcement on 9 New Substances, Including Codonopsis, That Are Traditionally Both Food and Chinese Medicinal Materials" (National Health Food Letter

[2023] No. 9), the "Local Food Safety Standard Gastrodia elata" (No.: DBS52 / 060-2022) issued by the Guizhou Provincial Health Commission, and research literature recommendations.

[0066] The corresponding doses were administered at 9 am on the day of the experiment:

[0067] a. Example test group, determined according to the corresponding dosage (recommended daily per capita consumption of Gastrodia elata 3-10g / d). Using the body surface area method for conversion, the conversion factor is 10, and the average human body weight is 60kg, and the dosage of this embodiment is determined to be 1.43g / kg BW (based on Gastrodia elata 10g / d). Directly use the ultrafine powder prepared in 4.3.1, according to the weight of mice, add water and weigh (after conversion, the concentration of Gastrodia elata is 0.8mg / mL), and the mouse gavage volume is 200-250uL (calculated according to the weight of mice).

[0068] b. Positive drug group was given an equal volume of dimenhydrinate suspension.

[0069] c. Normal control group, given an equal volume of normal saline.

[0070] 5.2 Establishment of Motion Sickness Mouse Model

[0071] One hour after drug administration, the mice in the remaining groups were placed in a balance rotator without restraint to simulate motion sickness stimulation.

[0072] The specific method is:

[0073] It rotates clockwise around the horizontal axis at a maximum speed of 100r / min. After running for 30s, it decelerates immediately, stops, and then rotates counterclockwise in the same way until the rotation stops. This is one rotation cycle. Each cycle lasts 60s, and the modeling process lasts for 1h.

[0074] At the same time, the mice in the normal group were placed next to the rotating modeling device for 1 hour. During the modeling period, the possible effects of noise, light, room temperature, humidity, etc. on the model were eliminated.

[0075] 5.3 Balance beam test

[0076] The balance beam is a wooden bar 100 cm long and 2 cm wide. The mouse cage is placed under the wooden bar for protection. The mice need to be trained for 3 consecutive days before the formal test. The mice are required to pass the balance beam in one direction without obvious pauses or turns. After the mice pass the balance beam, fruit jelly is provided as a reward. If the mouse defecates on the balance beam, the excrement needs to be cleaned and the smell needs to be wiped with ethanol.

[0077] The balance beam behavior of mice was calculated according to the Feeney scoring standard, and the time it took for the mice to move 80 cm on the balance beam was recorded as the passing time of the mice. If the mice did not pass, the time was recorded for 60 seconds.

[0078] Feeney scoring standard: 0 points means crossing the balance beam without falling; 1 point means crossing the balance beam with less than 50% chance of falling; 2 points means crossing the balance beam with more than 50% chance of falling; 3 points means being able to cross the balance beam, but the affected paralyzed hind limb cannot help move forward; 4 points means being unable to cross the balance beam, but being able to stop on it; 5 points means falling off the balance beam.

[0079] 5.4 Observation of dizziness index

[0080] After the mice were accelerated, the dizziness reaction index of the experimental mice was recorded immediately. The specific scoring criteria were as follows: ① fecal particles: 1 point for each particle, 0 point for none; ② urination: 1.2 points for urination, 0 point for none; ③ piloerection: 1.2 points for severe, 0.6 points for mild, 0 point for none; ④ tremor: 1.2 points for tremor, 0 point for none.

[0081] The dizziness index is the sum of all scores.

[0082] 5.5 Experimental observation of spontaneous activity

[0083] Place the mice after rotation stimulation in the spontaneous activity meter for 5 to 10 minutes, and measure the number of activities and the distance of activities of the mice. Place the mice in the center of the bottom surface of the box, and take pictures and time at the same time. Stop taking pictures after a certain period of observation. The observation time can be determined according to the experiment. Clean the inner wall and bottom surface of the box to prevent the remaining information (such as urine, feces, and odor) of the mice in the last test group from affecting the next test results.

[0084] Change the mice in the experimental group and continue the experiment.

[0085] 5.6 Animal Experiment Results and Analysis

[0086] 5.6.1 MSI Scoring Results

[0087] Motion sickness is usually accompanied by symptoms such as nausea, vomiting, and gastrointestinal discomfort. MSI has good accuracy and repeatability as an indicator for judging motion sickness in mice. The larger the MSI score, the more severe the degree of motion sickness.

[0088] Table 2 Effects of different embodiments on MSI in motion sickness mice

[0089]

[0090] As shown in Table 2, the dizziness index value of the mice in the model group was 5.05±0.89, and compared with 2.05±0.46 in the normal group, the MSI of the model group increased significantly (P<0.05), indicating that the modeling of this experiment was successful; compared with the model group, the dizziness index of the mice in Example 1-4 groups was significantly reduced (P<0.05), and at the same time, the model group had the highest number of defecations, which was significantly higher than the normal group and the positive drug group, while the number of defecations of the mice in Example 1-4 groups was less. The number of defecations can more intuitively evaluate the severity of the gastrointestinal reaction symptoms of mice when stimulated by motion sickness, and is also an important indicator for evaluating the effectiveness of the treatment method. The number of defecations of the mice in Example 1-4 groups of the present invention is significantly less than that of the model group.

[0091] 5.6.2 Balance beam test results

[0092] The balance beam test can detect changes in the motor coordination ability of mice. The balance beam behavior of mice in the examples of the present invention is shown in Table 3 below.

[0093] Table 3 Balance beam behavior record of mice in different embodiments (±s)

[0094]

[0095] As shown in Table 3, the balance beam score of the model group mice was 3.75±0.89, and they were basically unable to crawl through the balance beam smoothly. Compared with the model group, the balance beam scores of the mice in Example 1-4 groups were significantly reduced (P<0.05), and they were able to crawl through the balance beam smoothly; at the same time, the time for the mice in the model group to pass the balance beam was 46.45±16.45s, and the time for the mice in Example 1-4 groups to pass the balance beam was significantly shortened compared with the model group (P<0.05).

[0096] 5.6.3 Spontaneous activity test results

[0097] The behavioral manifestations of reduced spontaneous activity are similar to the mental depression and slow reaction after vertigo occurs. They indirectly reflect the changes in the central nervous system and can be used as a specific indicator for judging the occurrence of motion sickness.

[0098] Table 4 Total distance traveled in the open field by mice in different example groups (n=8)

[0099]

[0100]

[0101] As shown in Table 4, compared with 24.12±2.58m in the normal group, the total distance of spontaneous activity of mice in the model group was 1.86±0.26m, which was extremely significantly decreased (P<0.001); compared with the model group, the total distance of spontaneous activity of mice in Example 1-4 groups was significantly increased (P<0.05), and the mice in each Example group were in an active state within 10min, indicating that the Example group was less affected by the dizziness stimulation and could maintain a certain motor ability.

[0102] 5.6.4 Conclusion

[0103] The results of MSI, balance beam test and spontaneous activity test were consistent, indicating that the composition of the present invention has a significant anti-motion sickness effect within a given mass fraction range.

[0104] The formula of Comparative Examples 1-3 is shown in Table 5 below.

[0105] Table 5 Formula table of comparative examples 1-3

[0106]

[0107] 7 Animal experiments based on Comparative Examples 1-3 and Example 1

[0108] 7.1 Animal Experiment Grouping and Dosing

[0109] Balb / c mice were randomly divided into 5 groups, namely, model group, Example 1 group, Comparative Example 1, Comparative Example 2 and Comparative Example 3 group, with 8 mice in each group.

[0110] The drugs were administered at 9:00 am on the day of the experiment. The dosage was the same as that in 5.1a, and the intragastric volume was 0.2-0.25 mL. The model group was given an equal volume of normal saline.

[0111] 7.2 Establishment of motion sickness mouse model, same as above.

[0112] 7.3 Dizziness index test, same as above.

[0113] 7.4 Spontaneous activity test, same as above.

[0114] 7.5 Fatigue test

[0115] The container is a glass water tank of 30×20 cm, 30 cm high, 20 cm deep, and maintained at an air pressure of 0.61 atm.

[0116] A lead sheet weighing 6% of the mouse's body weight was fixed to the mouse's tail. The mouse's placement time, swimming time, and time when the mouse sank and stopped moving were recorded. The test endpoint was when the head was submerged in water for 6 seconds, and the mouse's exhaustive swimming time was recorded.

[0117] 7.6 Animal Experiment Results and Analysis

[0118] 7.6.1 MSI Scoring

[0119] The dizziness reaction index is the sum of all scores. The larger the dizziness reaction index is, the higher the degree of dizziness is.

[0120] Table 6 Comparative Example MSI Index Record Table

[0121]

[0122] As shown in Table 6, compared with the model group mice, the MSI index of the mice in the embodiment group was reduced by 53.9%, while the MSI index of the mice in the comparative example 1-3 groups was only reduced by 28.68%, 29.69% and 36.76%, respectively. The anti-motion sickness effect of the embodiment was the most significant.

[0123] 7.6.2 Analysis of spontaneous activity test results

[0124] Table 7 Comparative Example Spontaneous Activity Experiment Record

[0125]

[0126] As can be seen from Table 11, compared with the mice in the model group, the total distance of spontaneous activity of the mice in the embodiment group increased by 672.9%, while the total distance of spontaneous activity of the mice in the control groups 1-3 only increased by 35.8%, 312.58%, and 229.56%; the number of activities of the mice in the embodiment group significantly increased by 280.2%, while the number of activities of the mice in the control groups 1-3 only increased by 57.1%, 168.1%, and 110.1%, which is consistent with the results of the MSI experiment, indicating that the embodiments of the present invention have the most significant effect on relieving motion sickness in mice.

[0127] 7.6.3 Analysis of fatigue test results

[0128] Table 8 Comparative Exhaustive Swimming Time Record

[0129]

[0130] As shown in Table 8, compared with the mice in the model group, the exhaustive swimming time of the mice in the embodiment group was extended by 38.2%, while the exhaustive swimming time of the mice in the comparative examples 1-3 groups was only extended by 8.6%, 20.96%, and 11.83%. The improvement of exercise endurance is the most powerful macroscopic manifestation of anti-fatigue ability, and the length of the exhaustive swimming time can reflect the degree of animal exercise fatigue. The continuous swimming time of the mice in the embodiment group was significantly longer than that of the other comparative groups, indicating that the present invention has a more significant anti-fatigue effect.

[0131] 7.7 Conclusion

[0132] By comparing the MSI, balance beam, and spontaneous activity tests with the control examples, it can be concluded that the synergistic effect of Gastrodia elata, ginger, and ginseng in the efficacy composition of the present invention has a significant anti-motion sickness effect, while the anti-motion sickness effect of each of them acting alone is not significant;

[0133] At the same time, the weight-bearing swimming test shows that the effective composition of the present invention can significantly prolong the exhaustive swimming time of mice and has a significant anti-fatigue effect.

[0134] 8 Prepare the superfine powder composition prepared in 4.3.1 into food glue

[0135] 8.1.1 Preparation of mixed solution

[0136] According to the mass parts in Table 1 above, respectively weigh the ultrafine powders of Gastrodia elata, ginger, ginseng, rosemary, Poria cocos, spiny jujube seed, tamarind and tangerine peel, mix them, dissolve them in 50 mL of distilled water, place them in a 50°C water bath to dissolve, and cool to room temperature after complete dissolution to obtain a mixed solution.

[0137] 8.1.2 Preparation of food glue

[0138] Step A, according to the mass parts in Table 1 above, weigh 30g of superfine powder of Gastrodia elata, ginger, ginseng, rosemary, Poria cocos, spiny jujube seed, tamarind, and tangerine peel respectively, mix and dissolve in 50mL of distilled water, place in a 50°C water bath to dissolve, cool to room temperature after complete dissolution, and obtain a mixed solution for standby use.

[0139] Step B, weigh 20g of gelatin, add it into 50mL of distilled water, let it stand for 20min to dissolve, then heat it in a constant temperature 75℃ water bath, stir until the gelatin is fully dissolved, and prepare the gel solution, seal it with plastic wrap to keep it warm, and set aside.

[0140] Step C, weigh a certain amount of white sugar and fructose syrup, add them into 50 mL of distilled water, stir until fully dissolved, place on an electric stove and heat over low heat to boil to obtain sugar solution.

[0141] Step D, mixing the prepared sugar solution, gel solution and mixed solution evenly while hot, letting them stand for a while, injecting them into a mold while hot, and after cooling, obtaining a food gel of the composite.

[0142] 8.2 Sensory test of the food glue prepared in 8.1.2 is shown in Table 9 below:

[0143] Table 9 Evaluation of the appearance and taste of the food glue of Examples 1 to 4

[0144]

[0145] Comprehensive score, the full score is 10 points. As can be seen from Table 9, Example 1 has the highest score, which indirectly proves the role of auxiliary materials: the appropriate addition of auxiliary materials will make the product have better sensory experience. That is, the formula of Example 1 is the best optimized formula, which is 18 parts of Gastrodia elata, 5 parts of ginger, 5 parts of ginseng, 3 parts of rosemary, 3 parts of Poria cocos, 2 parts of Ziziphus jujuba seeds, 7 parts of tamarind, 1 part of dried tangerine peel, and an appropriate amount of sweetener.

[0146] 9 Based on the composition formulation of Example 1 with the best sensory organoleptic properties screened in sensory test 8.2, the following animal experiment was carried out to study its minimum effective dose.

[0147] 9.1 Animal Experiment Grouping and Dosing

[0148] The experimental group of the present invention was administered with high, medium and low doses at 9h in the morning of the day of the experiment (the high dose was 1.40g / kg BW, the medium dose was 1.00g / kg BW, and the low dose was 0.40g / kg BW), each time 0.2-0.25mL; the positive drug group was administered with an equal volume of dimenhydrinate suspension; the normal control group was administered with an equal volume of physiological saline. Ultrafine powder was used as the test material, and water was added and weighed according to the weight of the mouse (after conversion, the concentration of Gastrodia elata at a high dose of 1.40g / kg BW was 0.8mg / mL, and the medium dose and low dose were calculated in turn).

[0149] 9.2 Establishment of motion sickness mouse model, same as above.

[0150] 9.3 Balance beam test, same as above.

[0151] 9.4 Observation of dizziness reaction index, same as above.

[0152] 9.5 Experimental observation of spontaneous activity, same as above.

[0153] 9.6 Serum index testing should be carried out strictly according to the instructions of the ELISA kit product manual.

[0154] 9.7 Animal Experiment Results and Analysis

[0155] 9.7.1 MSI Scoring

[0156] Table 10 Effect on MSI in motion sickness mice

[0157]

[0158] As can be seen from Table 10, compared with the normal group, the dizziness index score of the model group mice was significantly increased (model group VS normal group, P = 0.0000 < 0.001), indicating that the motion sickness mouse model was successfully established. Compared with the model group, the MSI scores of the mice in the high, medium and low dose groups of the present invention were significantly reduced (P < 0.05), which were reduced by 55.8%, 53.9% and 43.4% respectively; the dizziness index score of the mice in the positive drug group was significantly reduced compared with the model group mice (P < 0.05), but there was no statistical significance compared with the low dose group of the present invention (P = 0.512 > 0.05). At the same time, the model group had the highest number of bowel movements, while the high dose group of the present invention had the least number of bowel movements, and these results were consistent with MSI.

[0159] 9.7.2 Balance beam test results

[0160] Table 11 Mouse balance beam behavior record (±s)

[0161]

[0162]

[0163] As can be seen from Table 11, compared with the normal group mice, the time for the model group mice to pass the balance beam was also significantly prolonged (P<0.05), and the balance beam score was significantly increased. Compared with the model group, the time for the mice fed with high, medium and low doses in the present invention group to reach the end of the balance beam from the starting end was significantly reduced (P<0.05), and they could crawl through smoothly, and the balance beam score was significantly reduced (P<0.05), and its effect was equivalent to that of the positive drug (P>0.05). It shows that after the intragastric intervention of the composition of the present invention, the mice were less affected by the dizziness stimulation, and could also maintain good balance ability and motor coordination ability.

[0164] 9.7.3 Spontaneous activity test results

[0165] Table 12 Total distance traveled in the open field by mice in each experimental group (n=8)

[0166]

[0167] As shown in Table 12, the total distance of spontaneous activity in the model group was significantly lower than that in the normal group (P<0.01), which also confirmed that the motion sickness mouse model was successful. Compared with the normal group, the total distance of spontaneous activity of mice in the high, medium and low dose groups of the present invention was significantly reduced (P<0.01), but the total distance of spontaneous activity of mice in the high, medium and low dose groups of the present invention was significantly higher than that in the model group (P<0.01), and the mice were more active than those in the model group; indicating that the composition of the present invention has a significant promoting effect on the spontaneous activity of motion sickness model mice, that is, it has a significant protective effect on motion sickness model mice.

[0168] 9.7.4 Serum index test results

[0169] like Figure 3 Shown is a bar graph of serum index levels, wherein A: histamine (HIS); B: acetylcholine (ACH); C: adrenocortical hormone (ACTH).

[0170] Compared with the normal group, the serum HIS, ACH, and ACTH levels of the mice in the model group increased significantly, reaching a very significant level (P<0.01). The neurotransmitter hypothesis believes that the increased release of ACH during the occurrence of motion sickness may be the main factor causing motion sickness. Compared with the model group, the serum HIS, ACH, and ACTH levels of the mice in the high, medium, and low dose groups of the present invention group decreased significantly (P<0.01 or P<0.05); at the same time, the serum HIS, ACH, and ACTH levels of the mice in the high dose group of the present invention were closest to those in the normal group, followed by the medium dose group.

[0171] In the interaction with noradrenergic neurons, if ACH neurons are in a dominant position, vomiting will be induced in the body. Gastrodin in Gastrodia elata has the effect of inhibiting the central excitatory transmitter ACH in the central nervous system, reducing the conduction of vestibular stimulation impulses to the cerebral cortex, thereby alleviating dizziness and nausea reactions. The above results show that the Gastrodia elata of the present invention can produce the effect of protecting brain neuron cells, inhibiting the conduction of nerve impulses to the vestibular lateral multisynaptic neurons, blocking adverse vestibular reflexes, avoiding the occurrence of dizziness, and thus effectively alleviating motion sickness.

[0172] 9.8 Conclusion

[0173] According to the "Announcement on 9 New Substances Including Codonopsis Pilosula That Are Traditionally Both Food and Chinese Medicinal Materials", DBS52 / 060-2022 "Local Food Safety Standard Gastrodia Elata" and the recommended daily per capita consumption of Gastrodia elata of 3-10g / d in research literature, the body surface area method was used to convert the maximum dosage of Gastrodia elata powder to 1.43g / kg BW, and the minimum dosage to 0.43g / kg BW.

[0174] In this example, the high dosage is 1.40 g / kg BW, the medium dosage is 1.00 g / kg BW, and the low dosage is 0.40 g / kg BW, which meet the relevant standards.

[0175] The test results show that within the effective dosage range, the high-dose and medium-dose anti-motion sickness effects of the present invention are better than those of positive drugs, and the anti-motion sickness efficacy of low doses is equivalent to that of positive drugs. In addition, the composition of the present invention is taken from plant-based medicinal and edible materials, will not produce toxic side effects in the human body, and has high safety.

[0176] 10. Application of combination

[0177] The composition of the present invention can also be used to prepare other types of functional foods, such as biscuits, jellies, soft candies and other foods in various forms.

[0178] The composition of the present invention can also be used to prepare medicines, such as mixing the ultrafine powder of gastrodia elata, ginger and ginseng with other medicinal excipients, or the ultrafine powder containing gastrodia elata, ginger, ginseng, rosemary, Poria cocos, spiny jujube seeds, tamarind and tangerine peel prepared in 4.3.1 with other medicinal excipients, and pressing them into granules, or making them into medicines such as capsules and medicinal drinks.

[0179] The composition of the present invention can also be used to prepare functional beverages, such as adding a mixed superfine powder of gastrodia elata, ginger, and ginseng into a flavored beverage, or adding a mixed solution of superfine powders of gastrodia elata, ginger, ginseng, rosemary, Poria cocos, spiny jujube seeds, tamarind, and tangerine peel prepared in 4.3.2 into a flavored beverage to prepare a functional beverage.

[0180] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.

Claims

1. A composition having both anti-motion sickness and anti-fatigue effects, characterized in that: By weight, it comprises: 10-20 parts of gastrodia elata, 2-8 parts of ginger, and 3-6 parts of ginseng.

2. The composition according to claim 1, characterized in that In terms of weight, the composition further includes 5-10 parts of tamarind, 0.5-2 parts of dried orange peel, 1-5 parts of spinach seeds, 2-5 parts of rosemary, and 1-5 parts of poria.

3. A method for preparing a composition having both anti-motion sickness and anti-fatigue effects, characterized in that: The components in claim 1 or 2 are added into a pulverizer and pulverized to obtain coarse powder; the coarse powder of each component is then pulverized into ultrafine powder with a particle size of 1-10 μm using a low-temperature cell-grade pulverizer, and the powders are mixed.

4. Use of the composition according to claim 3 in preparing functional foods.

5. Use of the composition according to claim 3 in the preparation of medicines.

6. Use of the composition according to claim 3 in preparing functional drinks.

7. Use of the composition according to claim 3 in food preparation.

Images